Literature DB >> 19250818

A new strategy to screen MMR genes in Lynch Syndrome: HA-CAE, MLPA and RT-PCR.

Lucia Perez-Cabornero1, Eladio Velasco, Mar Infante, David Sanz, Enrique Lastra, Lara Hernández, Cristina Miner, Mercedes Duran.   

Abstract

AIMS: Hereditary non-polyposis colon cancer (HNPCC) is an autosomal dominant disorder that is genetically heterogeneous because of underlying mutations in mismatch repair (MMR) genes, primarily MLH1, MSH2 and MSH6. One challenge to correctly diagnose HNPCC is that the large size of the causative genes makes identification of mutations both labour intensive and expensive.
METHODS: Our heteroduplex analysis by capillary array electrophoresis (HA-CAE) method, previously developed to increase the throughput and allow other multi-exon genes to be scanned, has been adapted for MMR genes. The altered peak patterns were then sequenced. Furthermore, the mutational scanning was completed using the Multiplex Ligation-Dependent Probe Amplification (MLPA) test in all negative HA-CAE cases, and these results were confirmed by RT-PCR.
RESULTS: We studied 216 individuals belonging to 100 unrelated families that met the Amsterdam I/II criteria for HNPCC. We detected 40 different variants that are classified as follows: 8 (20%) deleterious mutation, 8 (20%) unknown pathogenic significance variants and 24 (60%) coding and intronic sequence variants. Pathogenic mutations were detected in 12% of the families and about 42% of these had a deletion variant. Unknown pathogenic significance variants (UVs) affected 13% of the families. We also found 12.5% of novel polymorphisms in the rest of the variants. CONCLUDING: In short, using a combined method that includes HA-CAE, MLPA and RT-PCR, it is possible to detect the entire mutational spectrum of MMR genes. Twenty percent of the mutations found in the three genes have not been reported before. Relatives at risk will be offered predictive molecular analysis with potential exclusion of non-carriers of mutations.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19250818     DOI: 10.1016/j.ejca.2009.01.030

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  5 in total

1.  Oncologists' Selection of Genetic and Molecular Testing in the Evolving Landscape of Stage II Colorectal Cancer.

Authors:  Aparna R Parikh; Nancy L Keating; Pang-Hsiang Liu; Stacy W Gray; Carrie N Klabunde; Katherine L Kahn; David A Haggstrom; Sapna Syngal; Benjamin Kim
Journal:  J Oncol Pract       Date:  2016-03       Impact factor: 3.840

2.  Genotype-phenotype correlation in MMR mutation-positive families with Lynch syndrome.

Authors:  Lucía Pérez-Cabornero; Mar Infante; Eladio Velasco; Enrique Lastra; Cristina Miner; Mercedes Durán
Journal:  Int J Colorectal Dis       Date:  2013-04-16       Impact factor: 2.571

3.  Inhibitory effects of baicalin on orthotopic xenografts of colorectal cancer cells that are deficient in a mismatch repair gene in nude mice.

Authors:  Bo-Lin Yang; Hong-Jin Chen; Yu-Gen Chen; Yun-Fei Gu; Shu-Peng Zhang; Qiu Lin; Yu Sun
Journal:  Int J Colorectal Dis       Date:  2012-08-23       Impact factor: 2.571

4.  Frequency and variability of genomic rearrangements on MSH2 in Spanish Lynch Syndrome families.

Authors:  Atocha Romero; Pilar Garre; Olivia Valentin; Julian Sanz; Pedro Pérez-Segura; Patricia Llovet; Eduardo Díaz-Rubio; Miguel de la Hoya; Trinidad Caldés
Journal:  PLoS One       Date:  2013-09-11       Impact factor: 3.240

5.  Functional examination of MLH1, MSH2, and MSH6 intronic mutations identified in Danish colorectal cancer patients.

Authors:  Sanne M Petersen; Mette Dandanell; Lene J Rasmussen; Anne-Marie Gerdes; Lotte N Krogh; Inge Bernstein; Henrik Okkels; Friedrik Wikman; Finn C Nielsen; Thomas V O Hansen
Journal:  BMC Med Genet       Date:  2013-10-03       Impact factor: 2.103

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.